Margarita Majem, MD, PhD, a faculty member in the Department of Medical Oncology at the Hospital de la Santa Creu i Sant Pau, discusses the patient-reported outcomes with osimertinib (Tagrisso) in 

-mutated non–small cell lung cancer (NSCLC) from the pivotal phase 3 ADAURA trial.

Results from the phase 3 ADAURA trial, which examined the use of osimertinib in resected, 

-mutant NSCLC, indicated that patients who received osimertinib had significantly longer disease-free survival compared to patients who received a placebo.

At baseline, patients had nearly the same mean value of quality of life (QoL) as the general population, according to Majem, who virtually presented the findings during the 

. When patients were treated with osimertinib, QoL was maintained across all domains evaluated in the analysis, Majem concludes.

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


IASLC World Conference on Lung Cancer

Margarita Majem, MD, PhD, discusses the patient-reported outcomes with osimertinib in EGFR-mutated non–small cell lung cancer from the pivotal phase 3 ADAURA trial.



Dr. Majem on Patient-Reported Outcomes With Osimertinib in EGFR+ NSCLC